Cargando…

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors

PURPOSE: Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite recent advances in SK1 inhibitors synthesis and validation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshaker, Heba, Srivats, Shyam, Monteil, Danielle, Wang, Qi, Low, Caroline M. R., Pchejetski, Dmitri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208908/ https://www.ncbi.nlm.nih.gov/pubmed/30043096 http://dx.doi.org/10.1007/s10549-018-4900-1

Ejemplares similares

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017)

Sphingosine Kinase 1 in Breast Cancer—A New Molecular Marker and a Therapy Target
por: Alshaker, Heba, et al.
Publicado: (2020)

Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting
por: Alshaker, Heba, et al.
Publicado: (2019)

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
por: Wang, Qi, et al.
Publicado: (2017)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016)

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
por: Alshaker, Heba, et al.
Publicado: (2017)

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway
por: Alshaker, Heba, et al.
Publicado: (2014)

Bradycardia and syncope as sole manifestations of a cranial lesion: a case report
por: Pchejetski, Dmitri, et al.
Publicado: (2020)

A case of severe dry eye disease with corneal melting as presenting complaint of acute myeloid leukaemia
por: Pchejetski, Dmitri, et al.
Publicado: (2021)

The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)

An unusual case of disseminated intravascular coagulation
por: Pchejetski, Dmitri, et al.
Publicado: (2017)

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma
por: Alshaker, Heba, et al.
Publicado: (2015)

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
por: Pchejetski, Dmitri, et al.
Publicado: (2015)

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection
por: Nunes, J, et al.
Publicado: (2012)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Monocytes acquire prostate cancer specific chromatin conformations upon indirect co-culture with prostate cancer cells
por: Alshaker, Heba, et al.
Publicado: (2022)

Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists
por: Łupicka-Słowik, Agnieszka, et al.
Publicado: (2020)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
por: Yan, S. Betty, et al.
Publicado: (2017)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
por: Yan, S. Betty, et al.
Publicado: (2012)

Protein Kinase C Inhibition With Ruboxistaurin Increases Contractility and Reduces Heart Size in a Swine Model of Heart Failure With Reduced Ejection Fraction
por: Sharp, Thomas E., et al.
Publicado: (2017)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Location-specific and Kinase-Independent GRK5 Function in Heart
por: Wang, Yifan F., et al.
Publicado: (2022)

Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases
por: Gao, Peng, et al.
Publicado: (2012)

Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups
por: Alshaker, Heba, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
por: Capasso, Anna, et al.
Publicado: (2018)

Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
por: Tahiri, Andliena, et al.
Publicado: (2020)

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

A Role for Polo-Like Kinase 4 in Vascular Fibroblast Cell-Type Transition
por: Li, Jing, et al.
Publicado: (2021)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic
por: Apostolatos, André H., et al.
Publicado: (2019)

Drugging Sphingosine Kinases
por: Santos, Webster L., et al.
Publicado: (2014)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Design and Development of Novel Urea, Sulfonyltriurea, and Sulfonamide Derivatives as Potential Inhibitors of Sphingosine Kinase 1
por: Roy, Sonam, et al.
Publicado: (2020)

Pleiotropic Effects of Pyruvate Kinase M2 in Right Ventricular Failure and Pulmonary Arterial Hypertension
por: Christou, Helen
Publicado: (2022)

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
por: Liu, Yingmiao, et al.
Publicado: (2014)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Structure–Activity Relationships and Molecular Modeling of Sphingosine Kinase Inhibitors
por: Baek, Dong Jae, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o0mteoioi2memu7601o4b0mvds